Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S. -., Mitchell, E. P., Zwiebel, J. A., . . . Flaherty, K. T. (2019). Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol.
シカゴスタイル引用形Jhaveri, K L., et al. "Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-amplified Tumors Excluding Breast and Gastric/gastroesophageal Junction (GEJ) Adenocarcinomas: Results From the NCI-MATCH Trial (EAY131) Subprotocol Q." Ann Oncol 2019.
MLA引用形式Jhaveri, K L., et al. "Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-amplified Tumors Excluding Breast and Gastric/gastroesophageal Junction (GEJ) Adenocarcinomas: Results From the NCI-MATCH Trial (EAY131) Subprotocol Q." Ann Oncol 2019.